A recent study conducted at Mount Sinai Hospital has demonstrated the safety and effectiveness of the Menon Precision Prostatectomy (MPP), a surgical technique for treating prostate cancer while preserving urinary and sexual functions. The study, conducted between 2022 and 2023, revealed that 91% of patients maintained urinary continence and retained potency within one-year of surgery, with no intra-operative complications.
The study, approved by the local Institutional Review Board, included patients with intermediate-risk prostate cancer who met eligibility criteria and were interested in preserving their functional status post-surgery. Participants underwent MRI-fusion capsular biopsies to ensure there was no cancer in the anticipated remnant tissue. If cancer was found to extend beyond the capsule, MPP was not performed. Preoperative consultations and biopsies determined the precision dissection side. Patients ineligible for MPP were advised to undergo RP.
From August 2022 to December 2023, Drs. Tewari and Menon performed MPP on 20 patients. The median age was 63 years, and the median PSA level was 6.89 ng/ml. No patient had a cancer detected on follow-up biopsy or developed metastases till date.
This was the first external validation study for the MPP technique in the world, confirming results established in 120 men at the Vattikuti Urology Institute, where the procedure was developed. At a follow-up of 5 – 7 years, MPP is a valid option for men with intermediate-risk prostate cancer, who wish to optimize functional results.
Mount Sinai Hospital continues to be a leader in innovative cancer treatments, providing patients with advanced options that improve their quality of life.